LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Purpose

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC. A Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.

Conditions

  • Superficial Bladder Cancer
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
  • Non-muscle Invasive Bladder Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

BCG-unresponsive Patients: 1. BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without coexisting papillary Ta/T1 tumors who are ineligible for or have elected not to undergo cystectomy, and have experienced CIS disease within 12 months of treatment where: adequate BCG regimen consists of at least 2 courses of BCG where the first course (induction) must have included at least 5 or 6 doses and the second course may have included a re-induction (at least 2 treatments) or maintenance (at least 2 doses), and Cis must be documented or indicated by pathology Phase 2 Only: 2. BCG-Naïve or BCG-incompletely treated Patients with CIS or BCG-unresponsive, HG Ta/T1 papillary disease without CIS: -NMIBC with current Cis of the bladder, with or without coexisting papillary Ta/T1 NMIBC tumor(s), who are ineligible for or have elected not to undergo cystectomy, where: either: cohort 2a) no treatment with BCG but may have previously been treated with at least 1 dose of intravesical chemotherapy following transurethral resection of bladder tumor (TURBT) and Cis must be documented or cohort 2b) indicated by pathology incomplete BCG treatment (at least 1 dose and less than the 5+2 doses required for adequate dosing per Cohort 1) or cohort 3) patients who are BCG-unresponsive following adequate treatment, with HG Ta/T1 papillary disease without CIS. All Patients with High Grade NMIBC: 3. Patients who have previously been treated with a checkpoint inhibitor and failed treatment are eligible for inclusion 30 days post-treatment (Phase 1) or 3 months post-treatment (Phase 2). 4. Male or non-pregnant, non-lactating female, 18 years or older. 5. Women of childbearing potential must have a negative pregnancy test at Screening. 6. Female patients of childbearing potential must be willing to consent to using highly effective birth control methods; Male patients are required to utilize a condom for the duration of the study treatment through 3 months post-dose. 7. In Phase 2, for patients with T1 lesions may be eligible after repeat TURBT if pathology shows non-invasive (Ta or less) or no disease. 8. Performance Status: Eastern Cooperative Oncology Group 0, 1, and 2. 9. Hematologic inclusion: a. Absolute neutrophil count >1,500/mm3. b. Hemoglobin >9.0 g/dL. c. Platelet count >100,000/mm3. 10. Hepatic inclusion: a. Total bilirubin must be ≤1.5 x the upper limit of normal (ULN). b. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤2.5 x ULN. 11. Adequate renal function with creatinine clearance >30 mL/min 12. Prothrombin time and partial thromboplastin time ≤1.25 x ULN or within the therapeutic range if on anticoagulation therapy. 13. Must have satisfactory bladder function with ability to retain study drug for 60 minutes.

Exclusion Criteria

  1. Active malignancies (i.e., progressing or requiring treatment change in the last 24 months). Exceptions allowed under Sponsor review. 2. Concurrent treatment with any chemotherapeutic agent. 3. History of partial cystectomy. 4. Treatment with last therapeutic agent (including intravesical chemotherapy post-TURBT) within 30 days of Screening (prior to the screening biopsy). 5. Patients who have received systemic immunosuppressive medication including high-dose corticosteroids. 6. History of severe asthma or other respiratory diseases. 7. History of unresolved vesicoureteral reflux or an indwelling urinary stent. 8. History of unresolved hydronephrosis due to ureteral obstruction. 9. Participation in any other research protocol involving administration of an investigational agent within 30 Days prior to screening or any prior treatment of NMIBC with any investigational gene or immunotherapy agent. 10. History of external beam radiation to the pelvis or prostate brachytherapy within the last 12 months. 11. History of interstitial lung disease and/or pneumonitis in patients who have previously received a PD-1 or PD-L1 inhibitor therapy. 12. Evidence of metastatic disease. 13. History of difficult catheterization that in the opinion of the Investigator will prevent administration of EG-70. 14. Active interstitial cystitis on cystoscopy or biopsy. 15. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 16. Known human immunodeficiency virus, Hepatitis B, or Hepatitis C infection. 17. Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months). 18. Hypersensitivity to any of the excipients of the study drug. Exclusionary for Bladder Rinse cohorts: known allergy to polidocanol

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Phase 1
Dose escalation phase
  • Drug: EG-70 (phase 1)
    Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
    Other names:
    • Phase 1
  • Drug: Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
    Patients will receive via catheter a 50 mL volume of a 5-minute bladder rinse immediately prior to administration of 50 mL of detalimogene voraplasmid (EG-70) at the RP2D for 30 minutes. During the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles of the sudy intervention. One cycle lasts approximately 12 weeks. For Maintenance treatment, 2 doses of the study intervention will be administered as a bladder instillation per 12-week cycle.
    Other names:
    • Phase 1 Bladder Rinse
    • Surfactant
Experimental
Phase 2
Cohort 1: Recommended Phase 2 dose (RP2D) with eligible BCG-unresponsive NMIBC patients with CIS, up to 4 cycles of treatment with EG-70. Patients in Complete Response continue to Maintenance Treatment. Cohorts 2A, 2B and 3: RP2D with eligible high-risk NMIBC patients with CIS who are BCG-naïve, BCG-exposed (incompletely treated with BCG) or BCG-unresponsive HG Ta/T1 papillary disease without CIS
  • Drug: EG-70 (phase 2) Master Protocol
    Under the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles, of EG-70 at the RP2D defined in Phase 1, administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
    Other names:
    • Phase 2
Experimental
Phase 1 Substudy Surfactant Bladder Rinse
BCG-unresponsive NMIBC patients with CIS, up to 4 cycles of treatment with EG-70. Patients in Complete Response continue to Maintenance Treatment. Bladder Rinse Cohort: a 5-minute bladder rinse prior to administration of RP2D of detalimogene voraplasmid (EG-70) with a shortened administration time of 30 minutes.
  • Drug: Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
    Patients will receive via catheter a 50 mL volume of a 5-minute bladder rinse immediately prior to administration of 50 mL of detalimogene voraplasmid (EG-70) at the RP2D for 30 minutes. During the Treatment Period, patients will receive 4 instillations per cycle for up to 4 cycles of the sudy intervention. One cycle lasts approximately 12 weeks. For Maintenance treatment, 2 doses of the study intervention will be administered as a bladder instillation per 12-week cycle.
    Other names:
    • Phase 1 Bladder Rinse
    • Surfactant

Recruiting Locations

The University of Alabama at Birmingham Clinical Research Unit (CRU)
Birmingham, Alabama 35249

Mayo Clinic
Scottsdale, Arizona 85259

Arkansas Urology
Little Rock, Arkansas 72211

University of California - Irvine Medical Center
Irvine, California 92697
Contact:
Edward Uchio
euchio@uci.edu

UC San Diego Moores Cancer Center
La Jolla, California 92037
Contact:
Salmasi

USC/Norris Comprehensive Cancer Center
Los Angeles, California 90033
Contact:
Anne Schuckman
323-865-3700
anne.schuckman@med.usc.edu

Tower Urology
Los Angeles, California 90048
Contact:
Terry Williams
310-854-9898
williamst@towerurology.com

Om Research
San Diego, California 92123
Contact:
Alanna Gavriushina
858-430-1101
Alanna.gavriushina@uniohp.com

Colorado Clinical Research
Lakewood, Colorado 80228

The George Washington Medical Faculty Associates
Washington D.C., District of Columbia 20037
Contact:
Michael Whalen
202-741-2798
mwhalen@mfa.gwu.edu

University of Florida
Jacksonville, Florida 32209
Contact:
Kethandapatti Balaji
904-244-7340
kc.balaji@jax.ufl.edu

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
Miami, Florida 33136

Emory University
Atlanta, Georgia 30322
Contact:
Shreyas Joshi
404-778-4898
shreyas.joshi@emory.edu

Georgia Cancer Center at Augusta University
Augusta, Georgia 30912

Urology of Indiana
Greenwood, Indiana 46143

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Faith Rahman
913-588-2502
frahman2@kumc.edu

John Hopkins Hospital
Baltimore, Maryland 21287

Chesapeake Urology Research Associates
Hanover, Maryland 21076
Contact:
Rian Dickstein
rdickstein@cua.md

Brigham and Women's Hospital
Boston, Massachusetts 45227
Contact:
Mark Preston
MPRESTON@BWH.HARVARD.EDU

Henry Ford Health System
Detroit, Michigan 48202
Contact:
Johar Raza, MD
716-697-0305
jraza1@hfhs.org

Corewell Health Medical Group and Spectrum Health Hospitals
Grand Rapids, Michigan 49503
Contact:
Conrad Tobert
616-267-7333

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Marissa Twedt
612-626-6661
twedt050@umn.edu

Mayo Clinic
Rochester, Minnesota 55905
Contact:
Shah

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08901
Contact:
Packiam

New Jersey Urology, LLC
Voorhees Township, New Jersey 08043
Contact:
Gordon Brown
gbrown@njurology.com

Albany Medical College
Albany, New York 12208

Roswell Park Cancer Institute
Buffalo, New York 14263

Mount Sinai Medical Center
New Haven, New York 10029
Contact:
John Sfakianos
john.sfakianos@mountsinai.or

Associated Medical Professionals of NY,
Syracuse, New York 13210

UNC Chapel Hill Hospital
Chapel Hill, North Carolina 27514
Contact:
Marc Bjurlin
919-966-8217
marc_bjurlin@med.unc.edu

Duke Health - Duke Cancer Center
Durham, North Carolina 27710

Associated Urologists of North Carolina
Raleigh, North Carolina 27612
Contact:
Mark Jalkut
919-782-1255
mjalkut@gmail.com

University of Cincinnati Medical Center
Cincinnati, Ohio 45219
Contact:
Mohammed Kamel
513-558-0983
kamelme@ucmail.uc.edu

Central Ohio Urology Group
Gahanna, Ohio 43230

Clinical Research Solutions - Helios Clinical Research
Middleburg Heights, Ohio 44130
Contact:
Kara Lasorella
440-340-9010
kara.lasorella@heliosclinical.com

Oregon Health & Science University (OHSU)
Portland, Oregon 97239
Contact:
J Liu
610-659-7113
jenj@ohsu.edu

Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania 19107

Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina 29572
Contact:
Neal Shore
843-449-1010
nshore@auclinics.com

Urology Associates, P.C.
Nashville, Tennessee 37209
Contact:
Jayram

Vanderbilt Univerity Medical Center
Nashville, Tennessee 37232
Contact:
Chang

Urology Austin
Austin, Texas 78745

UT Southwestern Medical Center
Dallas, Texas 75390
Contact:
Jose Santoyo
214-645-8764
jose.santoyo@utsouthwestern.edu

Houston Metro Urology
Houston, Texas 77027
Contact:
Gelpi-Hammerschmidt

Houston Methodist Hospital - Department of Urology
Houston, Texas 77030
Contact:
Taliah Muhammad
346-238-4523
tnmuhammad@houstonmethodist.org

University of Texas - MD Anderson Cancer Center
Houston, Texas 77030
Contact:
Ashish Kamat, MD
713-792-3250
akamat@mdanderson.org

Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah 84112

University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia 22903
Contact:
Christine Ibilibor
ci5d@uvahealth.org

Froedtert Hospital / Medical College of Wisconsin
Milwaukee, Wisconsin 52336
Contact:
Scott Johnson
414-955-0867
scjohnson@mcw.edu

More Details

Status
Recruiting
Sponsor
enGene, Inc.

Study Contact

enGene clinical trials
+18572991097
clinicaltrials@engene.com

Detailed Description

EG-70 is a novel non-viral gene therapy. EG-70 is designed to elicit a local immune response following delivery of the study gene therapy to the bladder urothelium. This approach of local administration through bladder instillation has the potential to induce a potent immune response exclusively at the site of the tumor, resulting in greater therapeutic benefit while reducing undesirable systemic toxicity. Eligible BCG-unresponsive NMIBC with CIS patients will be enrolled in Phase 1, and Cohort 1 of Phase 2. Eligible high-risk NMIBC patients will be enrolled in Phase 2 into separate cohorts include: BCG-naïve patients or BCG-exposed (incompletely treated) patients with Carcinoma in situ (CIS), and BCG-unresponsive HG Ta/T1 papillary disease without CIS. Patients will be treated for up to four 12-week cycles of study drug instillation doses and assessments with follow up assessments. Patients with complete response following four treatment cycles will enter up to 8 maintenance treatment cycles.